Revvityvs.Thermo Fisher Scientific
RVTY vs TMO · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Thermo Fisher Scientific is about 14× larger than Revvity by market cap; Thermo Fisher Scientific trades at the lower P/E (34.9 vs 72.6); year to date, Revvity leads (+57.3% vs +12.5%).
Side by side
| RVTY | TMO | |
|---|---|---|
| Market cap | $17.2B | $243B |
| Price | $154.18 | $658.02 |
| Today | +1.3% | +0.9% |
| Return YTD | +57.3% | +12.5% |
| Return 1Y | +65.8% | +21.6% |
| Since June 26, 2026 | +36.4% | +28.3% |
| P/E | 72.6 | 34.9 |
| P/S | 5.9 | 5.2 |
| P/B | 2.4 | 4.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
RevvityRVTY
Newborn and genetic screening is the clinical end of the business; the rest supplies reagents and software to research laboratories.
Full RVTY profile →Thermo Fisher ScientificTMO
Analytical instruments on one side, the reagents and consumables that feed them on the other, sold to research laboratories and pharmaceutical companies. Patheon, its contract manufacturing arm, makes drugs for customers outright.
Full TMO profile →More RVTY & TMO comparisons
Other head-to-heads in the Life science tools segment.